Ultimately, a personalized treatment paradigm that aligns regimens with each tumor’s evolving molecular landscape—and expands clinical trial designs to encompass real-world diversity—could not only delay or overcome resistance but also improve survival and quality of life for patients with EGFR-mutant NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.